Ausgabe 3/2017
Inhalt (12 Artikel)
Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line
Manisha Gupte, Prachi Umbarkar, Hind Lal
Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes
Nadjib Hammoudi, Dongtak Jeong, Rajvir Singh, Ahmed Farhat, Michel Komajda, Eric Mayoux, Roger Hajjar, Djamel Lebeche
The Role of MKP-1 in Insulin-Induced Cardioprotection
Ingrid Webster, Angelique Smith, Amanda Lochner, Barbara Huisamen
Argatroban Attenuates Diabetic Cardiomyopathy in Rats by Reducing Fibrosis, Inflammation, Apoptosis, and Protease-Activated Receptor Expression
Yogesh Bulani, Shyam Sunder Sharma
Plasma Lipidome Analysis by Liquid Chromatography-High Resolution Mass Spectrometry and Ion Mobility of Hypertriglyceridemic Patients on Extended-Release Nicotinic Acid: a Pilot Study
Véronique Ferchaud-Roucher, Mikaël Croyal, Thomas Moyon, Yassine Zair, Michel Krempf, Khadija Ouguerram
Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial
Licette C. Y. Liu, Mattia A. E. Valente, Douwe Postmus, Christopher M. O’Connor, Marco Metra, Howard C. Dittrich, Piotr Ponikowski, John R. Teerlink, Gad Cotter, Beth Davison, John G. F. Cleland, Michael M. Givertz, Daniel M. Bloomfield, Dirk J. van Veldhuisen, Hans L. Hillege, Peter van der Meer, Adriaan A. Voors
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect
Patrícia O. Guimarães, Renato D. Lopes, Daniel M. Wojdyla, Azmil H. Abdul-Rahim, Stuart J. Connolly, Greg C. Flaker, Junyuan Wang, Michael Hanna, Christopher B. Granger, Lars Wallentin, Kennedy R. Lees, John H. Alexander, John J.V. McMurray
Primary Care Physician Perspectives on Barriers to Statin Treatment
Rikki M. Tanner, Monika M. Safford, Keri L. Monda, Benjamin Taylor, Ronan O’Beirne, Melanie Morris, Lisandro D. Colantonio, Ricardo Dent, Paul Muntner, Robert S. Rosenson
The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease
Wassim Mosleh, Abhinav Sharma, Mandeep S. Sidhu, Brian Page, Umesh C. Sharma, Michael E. Farkouh
Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role
Dimitrios Alexopoulos, Panagiotis Vlachakis, John Lekakis
Human iPSC-Derived Cardiomyocytes for Investigation of Disease Mechanisms and Therapeutic Strategies in Inherited Arrhythmia Syndromes: Strengths and Limitations
Simona Casini, Arie O. Verkerk, Carol Ann Remme
MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications
Nicoline W. E. van den Berg, Makiri Kawasaki, Wouter R. Berger, Jolien Neefs, Eva Meulendijks, Anke J. Tijsen, Joris R. de Groot